Pluristem Life Systems, Inc.
Expansion of haematopoietic stem cells from cord blood, which can be used for bone marrow transplantations in treating a broad range of complicated diseases.
Pluristem Ltd. was founded by Dr. Shai Meretzki and colleagues following five years of research and development at the Technion Israel Institute of Technology in cooperation with the Weizmann Institute of Science. The company has developed a unique technology (PluriX™)for the expansion of stem cells, T-cells, and other blood-related cells.
Zami Aberman, CEO
Shai Meretzki, Dr., CTO
Yaky Yanay, CFO
Zami Aberman, Chairman
Doron Shorrer
Isaac Braun
Israel Ben Yoram
Have Klemperer Meretzki
Jacob M. Rowe, Prof., MD
Arnon Nagler, Prof., MD, MSc.
Edwin M. Horwitz, MD, PhD
Avinoam Kadouri, Dr.
Abraham Treves, Dr.
MATAM Advanced Technology Park,
Buliding No. 20
Haifa 31905
Israel
Phone: +972-4-850-1080
Fax: +972-4-850-1085
Pluristem has developed a unique process using its proprietary PluriX™ bioreactor system. This technology is based on a plug-flow bioreactor system that allows the growth of 3-D stromal cell cultures in an artificial physiological structure, which is very similar to the natural bone marrow environment. The HSCs are kept enclosed within the 3-D stromal cells environment; therefore, the cells maintain their original form and proliferate without differentiating.
The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.
Related patents
Related news
- Pluristem's Second Pre-Clinical Study in Ischemic Stroke Shows Statistically Significant Advantages in Functional and Anatomical Recovery
- Pluristem and Center for Regenerative Therapies at Charite University Hospital of Berlin Enters into Collaborative Research Agreement
- Pluristem Receives $830,000 Grant from Israeli Government for Development of the PLX-I Stem Cell Product
- Pluristem Acquires Patents and Technology for the Three Dimensional Expansion of Human Cells
- Pluristem Shares Commence Trading on Frankfurt Stock Exchange
- Pluristem Upgrading Its Manufacturing Facility to Support $200 Million in Production Capacity for PLX - I
- Pluristem Announces Scientific Advance in Stem Cell Research; Evidence That PLX Cells Are Immunosuppressive
- Pluristem Life Systems, Inc. Announces First Licensing Agreement and Stock Swap With Stem Cell Innovations, Inc.
- Pluristem Announces Evidence That PLX-I Cells Are Immune Privileged
- Pluristem Announces Evidence That PLX-I Cells Are Immune Privileged
- Pluristem Submits Pre-Investigational New Drug Document to FDA
- Pluristem to Present at Annual Meeting of American Society of Hematology: Breakthrough Method Improves Engraftment of Umbilical Cord Blood in Treating Severe Blood Disorders.
- Pluristem Appoints Yaky Yanay Chief Financial Officer.
- Pluristem Completes Conversion of Outstanding Convertible Debentures
- Pluristem Upgrades Manufacturing Facilities to Enable Production of First Biological Product for Phase I Clinical Trials
- Pluristem Initiates Pre-Clinical Study for PLX-1, an Innovative Stem Cell Solution for Improved Engraftment During Bone Marrow Transplantation
- Pluristem Files Patent Application For Expanding Hematopoeitic Stem Cells (HSC) and Early Progenitor Cells from Cord Blood Non Selected Mono-Nuclear Cells (MNC)
- Pluristem Ignites Technological Innovation in the Selection and Separation of Hematopoetic Stem Cells from Cord Blood for Bone Marrow Transplantation
- Pluristem Obtains Notice of Allowance from U.S. Patent Office Providing Broad Coverage of Proprietary Stem Cell Expansion Technology
- Pluristem Retains Stem Cell Leader Dr. Avraham Treves to Consult On Development of Its Products and Technology
- Pluristem Chosen To Present At The International Society for Experimental Hematology Annual Meeting -- New Orleans, July 2004
- Pluristem Announces Appointment of Dr. Menachem Ze'evi As CEO